Introduction
The BIOSECURE Act, signed into law on December 18, 2025 as Section 851 of the National Defense Authorization Act for Fiscal Year 2026, represents the most significant regulatory intervention in the global CDMO landscape in decades. By restricting what US agencies can buy, fund, and contract for when a supplier relies on designated Chinese biotechnology companies of concern, it is forcing a restructuring of pharmaceutical supply chains and a wave of reshoring investment that benefits Western CDMOs.
What the Act Does
The BIOSECURE Act targets Chinese biotechnology companies whose ownership, military affiliations, and data collection practices are treated as national security risks. The enacted text names no company, though earlier House and Senate drafts did, and WuXi AppTec, WuXi Biologics, BGI Genomics, MGI Tech, and Complete Genomics are still the names the market prices in. Designation runs through two routes: an interagency process led by the Office of Management and Budget, which must publish the first list of biotechnology companies of concern within a year of enactment, and an automatic hook to the Pentagon's Section 1260H list of Chinese military companies.
The reach also goes past ordinary procurement. Agencies cannot obligate loan or grant funds for covered equipment or services either, which turns a supplier choice into a funding condition for any biotech living on NIH or BARDA money.
- BIOSECURE Act Transition Period
The Act does not switch on at signature. Prohibitions start 60 days after the Federal Acquisition Regulation is revised for companies pulled in through the 1260H list, and 90 days after for companies designated through the OMB process. Contracts signed before that effective date, including previously negotiated options, sit outside the pass-through prohibition for a further five years. That runway reflects the practical reality that moving pharmaceutical manufacturing requires CMC supplements, FDA review, and process revalidation, all of which take 12-24+ months per product.
The signal effect is broader than the legal text. Large pharma selling into both government and commercial markets is diversifying away from designated providers rather than running dual supply chains, and biotechs raising US capital are now asked to show a BIOSECURE-compliant supply chain in diligence.
The Designation Clock and the 1260H Trigger
The mechanism moved from theory to practice on June 8, 2026, when the Pentagon added WuXi AppTec to its annual 1260H list of Chinese military companies, citing indirect state ownership and defense-industrial affiliations. WuXi AppTec disputes the designation. The listing satisfies the first statutory condition for treatment as a biotechnology company of concern, but nothing is prohibited yet. OMB must publish its list by December 2026, issue guidance within 180 days of that list, and the Federal Acquisition Regulatory Council then has up to a year to rewrite the rules. On those outside dates the prohibitions bite around 2028, with the grandfather window running into the early 2030s.
That gap between designation and enforcement is the commercial story. Nobody is cut off tomorrow, but a partner picked in 2026 supplies a product still selling in the 2030s, so the capacity decisions are being made now.
The Reshoring Investment Wave
BIOSECURE Act pressure, broader US-China decoupling, tariff threats on imported medicines, and pandemic-era supply chain scars have together triggered massive investment in domestic pharmaceutical manufacturing. Disclosed investment in CDMO capacity reached $24.86 billion globally in 2025, with the US taking 74% of it (roughly $18.5 billion), according to PharmaSource's tally of 2025 capacity announcements. Captive investment by large pharma runs larger still: Eli Lilly lifted the budget for its Lebanon, Indiana API site to $9 billion and committed a further $27 billion to four new US plants in February 2025, Novo Nordisk is adding API and fill-finish capacity in North Carolina and Denmark, and Samsung Biologics keeps expanding drug substance capacity in South Korea.
The reshoring trend extends beyond the US. "Friend-shoring" (relocating manufacturing to geopolitically allied nations rather than bringing it all domestic) is emerging as the pragmatic middle path. South Korea, Singapore, Ireland, and Switzerland are picking up both CDMO capacity builds and captive biopharma facilities.
The reshoring thesis has not yet dented the incumbent, and interviewers notice a candidate who knows that. WuXi AppTec posted record 2025 revenue of RMB 45.46 billion with backlog up almost 30% year on year, because approved products already validated in China are the most expensive ones to move. The demand shock lands first on new programs and second-source qualifications.
The next article covers the life sciences tools business model, exploring the razors-and-blades economics and spec-in lock-in that define the instruments and consumables companies.
